Cannabigerol, Making Food Appetizing for Cancer Patients

For all of the states that initially passed medical cannabis legislation, cancer was not only an approved condition but also a major data point supporting such legislation. Specifically, cancer patients, forced to undergo exhausting chemotherapy treatments, lose appetite. This drastic, prolonged loss of appetite, similar to anorexia, decreases body weight and in turn, decreases overall health. Cannabis has long been observed to increase appetite in humans (we’ve written several Cornerstone blog posts on the “munchies”), with the most active ingredient identified as THC, the psychoactive component of cannabis. Unfortunately, not all patients enjoy or can tolerate this psychoactivity. Originally, this posed a serious downside to treatment with cannabis. However, with the discovery of the endocannabinoid system, researchers realized that the effects of THC might be achieved, without psychoactivity, via other cannabinoids. Additionally, research has confirmed that cannabis containing no THC can still restore appetite. In line with this thinking, one paper, published last month in the medical research journal, Psychopharmacology, tested a molecule known as cannabigerol (CBG) on rodents to observe changes in feeding patterns. Readers may be surprised to learn that cannabigerol, unlike many other cannabinoids, found mostly in the resin of medicinal plants, exists in higher concentrations in plain hemp. Most medicinal strains, in fact, have concentrations lower than 1%. CBG also binds to the CB1 receptor at a much lower rate than THC and may even serve to temporarily disable the receptor. However, CBG has also been shown to be a 5-HT1A receptor agonist and an alpha2-adrenergic…